Published : October 18 2013 at 9:38 ET

Cepheid (CPHD) is having a buyable gap up. CPHD anticipates adjusted earnings loss of 22 to 24 cents per share for the year, better than analyst forecasts of a loss of 29 cents per share. It raised its revenue forecast for the year, saying it now expects revenue between $389 million and $391 million, also topping market expectations for $383.5 million.

CPHD develops automated molecular analysis systems for the clinical diagnostic, industrial, and biothreat markets. Its systems rapidly identify infection diseases and cancers.

We own a position in CPHD. It is a biotech with no earnings but growing sales. Position size accordingly.

This information is provided by Virtue of Selfish Investing, LLC (VoSI) is issued solely for informational purposes and does not constitute an offer to sell or a solicitation of an offer to buy securities. Information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of available data. VoSI reports are intended to alert VoSI members to technical developments in certain securities that may or may not be actionable, only, and are not intended as recommendations. Past performance is not a guarantee, nor is it necessarily indicative, of future results. Opinions expressed herein are statements of our judgment as of the publication date and are subject to change without notice. Entities including but not limited to VoSI, its members, officers, directors, employees, customers, agents, and affiliates may have a position, long or short, in the securities referred to herein, and/or other related securities, and may increase or decrease such position or take a contra position. Additional information is available upon written request. This publication is for clients of Virtue of Selfish Investing, LLC. Reproduction without written permission is strictly prohibited and will be prosecuted to the full extent of the law. ©2016 Virtue of Selfish Investing, LLC. All rights reserved.